RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
Melanoma is a type of malignant tumor derived from melanocytes, most of which occur in the skin, and a few occur in the mucosa and choroid. BRAF mutations occur in approximately 50% of melanoma patients. Vemurafenib is a specific and potent BRAF inhibitor that significantly prolongs progression-free...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Series: | Data in Brief |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340920305047 |
| _version_ | 1818063216360554496 |
|---|---|
| author | Kun Zhao Yanrong Lu Younan Chen Jingqiu Cheng Wengeng Zhang |
| author_facet | Kun Zhao Yanrong Lu Younan Chen Jingqiu Cheng Wengeng Zhang |
| author_sort | Kun Zhao |
| collection | DOAJ |
| description | Melanoma is a type of malignant tumor derived from melanocytes, most of which occur in the skin, and a few occur in the mucosa and choroid. BRAF mutations occur in approximately 50% of melanoma patients. Vemurafenib is a specific and potent BRAF inhibitor that significantly prolongs progression-free survival in patients with BRAF mutant melanoma. But most patients have tumor recurrence after 7-9 months. Drug resistance severely limits the long-term clinical effects of targeted drugs. To explore the mechanism of melanoma resistance to Vemurafenib, the transcripts of Vemurafenib-resistant melanoma A375R cells and the parental A375 cells were sequenced. For more insight please see Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells [1]. RNA-seq data has been uploaded to Sequence Read Archive (SRA), which allows researchers to obtain RNA sequence data for these cells. |
| first_indexed | 2024-12-10T14:16:35Z |
| format | Article |
| id | doaj.art-2ad69fa46b7b46578ce22cb24e9aab8a |
| institution | Directory Open Access Journal |
| issn | 2352-3409 |
| language | English |
| last_indexed | 2024-12-10T14:16:35Z |
| publishDate | 2020-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Data in Brief |
| spelling | doaj.art-2ad69fa46b7b46578ce22cb24e9aab8a2022-12-22T01:45:19ZengElsevierData in Brief2352-34092020-06-0130105610RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cellsKun Zhao0Yanrong Lu1Younan Chen2Jingqiu Cheng3Wengeng Zhang4Key Laboratory of Transplant Engineering and Immunology, NHFPC; Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaKey Laboratory of Transplant Engineering and Immunology, NHFPC; Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaKey Laboratory of Transplant Engineering and Immunology, NHFPC; Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaKey Laboratory of Transplant Engineering and Immunology, NHFPC; Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaPrecision Medicine Key Laboratory of Sichuan Province and Precision Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Corresponding author.Melanoma is a type of malignant tumor derived from melanocytes, most of which occur in the skin, and a few occur in the mucosa and choroid. BRAF mutations occur in approximately 50% of melanoma patients. Vemurafenib is a specific and potent BRAF inhibitor that significantly prolongs progression-free survival in patients with BRAF mutant melanoma. But most patients have tumor recurrence after 7-9 months. Drug resistance severely limits the long-term clinical effects of targeted drugs. To explore the mechanism of melanoma resistance to Vemurafenib, the transcripts of Vemurafenib-resistant melanoma A375R cells and the parental A375 cells were sequenced. For more insight please see Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells [1]. RNA-seq data has been uploaded to Sequence Read Archive (SRA), which allows researchers to obtain RNA sequence data for these cells.http://www.sciencedirect.com/science/article/pii/S2352340920305047MelanomaBRAFVemurafenibresistanceRNA-seq |
| spellingShingle | Kun Zhao Yanrong Lu Younan Chen Jingqiu Cheng Wengeng Zhang RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells Data in Brief Melanoma BRAF Vemurafenib resistance RNA-seq |
| title | RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells |
| title_full | RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells |
| title_fullStr | RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells |
| title_full_unstemmed | RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells |
| title_short | RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells |
| title_sort | rna sequencing data of vemurafenib resistant melanoma cells and parental cells |
| topic | Melanoma BRAF Vemurafenib resistance RNA-seq |
| url | http://www.sciencedirect.com/science/article/pii/S2352340920305047 |
| work_keys_str_mv | AT kunzhao rnasequencingdataofvemurafenibresistantmelanomacellsandparentalcells AT yanronglu rnasequencingdataofvemurafenibresistantmelanomacellsandparentalcells AT younanchen rnasequencingdataofvemurafenibresistantmelanomacellsandparentalcells AT jingqiucheng rnasequencingdataofvemurafenibresistantmelanomacellsandparentalcells AT wengengzhang rnasequencingdataofvemurafenibresistantmelanomacellsandparentalcells |